Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03847974 · ClinicalTrials.gov registry record · Phase 2
Open-Label Extension to Evaluate the Longer Term Efficacy and Safety of LIB003
A Phase 2 study of Hypercholesterolemia, sponsored by LIB Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
- 3
- Study locations
NCT03847974 is a Phase 2 study of Hypercholesterolemia that has completed, run by LIB Therapeutics. The registered enrollment target is 32 participants, below the 816-participant average among 62 other Hypercholesterolemia trials with a reported enrollment target (96% lower). The trial reports 3 study locations across 1 state.
The verdict
NCT03847974, a Phase 2 study of Hypercholesterolemia, has completed, sponsored by LIB Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
- 3
- Study locations
Study Summary
To assess the longer term safety, tolerability, and LDL C lowering efficacy after 52 weeks of additional treatment with LIB003 with subcutaneous (SC) dosing every 4 weeks (Q4W)
Conditions Studied
Interventions
- DRUG LIB003
Study Locations (3)
Ohio
- Sterling Research Group - Cincinnati
- The Lindner Research Center - Cincinnati
- Metabolic & Atherosclerosis Research Center (MARC) - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2019-02-14 |
| Est. Completion | 2020-08-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03847974
The ClinicalTrials.gov registry entry for NCT03847974 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 816-participant average among 62 other Hypercholesterolemia trials with a reported enrollment target (96% lower). The listed sponsor is LIB Therapeutics, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hypercholesterolemia appearing as the primary indexed condition, and to 1 intervention - of which LIB003 is the first listed.
NCT03847974 reports 3 study locations spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT03847974 about?
NCT03847974 is a clinical study titled "Open-Label Extension to Evaluate the Longer Term Efficacy and Safety of LIB003". To assess the longer term safety, tolerability, and LDL C lowering efficacy after 52 weeks of additional treatment with LIB003 with subcutaneous (SC) dosing every 4 weeks (Q4W)
What is the current status of trial NCT03847974?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2019-02-14. Estimated completion is 2020-08-31.
What conditions does trial NCT03847974 study?
This clinical trial studies the following conditions: Hypercholesterolemia.
What interventions are being tested in trial NCT03847974?
The interventions under investigation include: LIB003 (DRUG).
Who is sponsoring clinical trial NCT03847974?
This trial is sponsored by LIB Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03847974 being conducted?
This trial has 3 study locations across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypercholesterolemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders Trial
RECRUITING · Phase 2
-
The Safety & Efficacy of Combination BMS-201038 (AEGR-733) & Ezetimibe vs. Monotherapy in Moderate Hypercholesterolemia
COMPLETED · Phase 2
-
Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg, Ezetimibe 10mg, and Atorvastatin 20 mg Triplet Therapy in Patients With Elevated LDL-C
COMPLETED · Phase 2
-
Open-Label Extension of Study R727-CL-1003 (NCT01266876) to Evaluate the Long-Term Safety and Efficacy of Alirocumab (REGN727) in Participants With Heterozygous Familial Hypercholesterolemia (HeFH)
COMPLETED · Phase 2
-
Evaluation of ETC-1002 in Participants With Hypercholesterolemia and Hypertension
COMPLETED · Phase 2
-
Pilot Study To Assess CAT-2003 in Patients With Hyperlipidemia
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.